The U.S. market remains in a Confirmed Uptrend. This week, the S&P 500 rose 1.9%, while the Nasdaq gained 3.5% this week and both indices pushed back into all-time highs. Immediate support at rising 10-DMAs (5,489/17,875), with the next level of support at rising 21-DMAs (5,446/17,668). The distribution day count stands at two on both the indices after one expired due to time at the end of the week.
Author: Raj Gupta
O’Neil Health Care Weekly
XLV declined 72 bps last week, still holding support at its rising 21-DMA ($145.86) with next support at its 100-DMA ($144.29).
Resistance is at $147.16 before all-time highs of $148.27. Though Health Care is the second best performing sector behind
Technology over the trailing 8-weeks, its RS line remains in a long-term downtrend, still warranting an equal-to-underweight sector
positioning. We will be looking for the sector to break into new highs before recommending an overweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 was essentially flat this week while the Nasdaq rose ~20 bps. Indices are just below all-time highs and are testing 10-DMA support (5,454/17,681) after staging a downside reversal on Friday. The next level of support is at the rising 21-DMA (5,409/17,453) which is 1-2% lower. The distribution day count stands at three and four, respectively.
O’Neil Health Care Weekly
XLV gained 64bps last week holding support at its rising 21-DMA ($145.43). Resistance is at $147.16 before all-time highs of $148.27. Though Health Care is the third best performing sector behind Technology and Retail over the trailing 4-weeks, its RS line remains in a long-term downtrend, still warranting an equal-to-underweight sector positioning. We will be looking for the sector to break into new highs before recommending an overweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. Indices remain near all-time highs with the first level of support at the rising 10-DMA (5,429/17,572), followed by the 21-DMA (5,373/17,242). The distribution day count stands at four on each index with one and two days set to expire on the S&P 500 and Nasdaq, respectively, next week.
O’Neil Health Care Weekly
XLV declined 38bps last week, consolidating gains above 21-DMA ($145) support. Near-term resistance is $146.95 followed by all time highs of $148.27.
Market View
The U.S. market remains in a Confirmed Uptrend. This week, indices rallied, with the S&P 500 and the Nasdaq rising 1.6% and 3.2%, respectively. The first level of support is at the rising 10-DMA (5,365/17,268), followed by the 21-DMA (5,326/17,054). The distribution day count stands at three and four, respectively.
O’Neil Health Care Weekly
XLV gained 1.9% for the week and is now testing near-term resistance at $146.95 before all-time highs of $148.27. Near-term support is along the rising 21-DMA ($144.35). Though the sector is the 5th best performer over the trailing 4-weeks (+2%), its RS line has yet to make a higher high, remaining in a longer-term downtrend. We will be looking for the sector to break into new highs before recommending an overweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq are chopping around near all-time highs after
rallying ~1.3% and ~2.3%, respectively. The first level of support is at the rising 10-DMA (5,311/16,959), followed by the 21-DMA
(5,276/16,7687). The distribution day count stands at three and four, respectively.
O’Neil Health Care Weekly
XLV ended the week down 50bps, despite rallying 1.5% Friday to regain its 50-DMA ($142.78). This level will now act as near-term support with the range of resistance unchanged between $147 to $148.27 (all-time high). Its RS line (vs. the S&P 500 and Nasdaq) remains near lows, still warranting an underweight sector positioning.